Online inquiry

IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8434MR)

This product GTTS-WQ8434MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets HSP90 gene. The antibody can be applied in Candidiasis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq XP_721353.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3636951
UniProt ID P46598
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8434MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2103MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ5412MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ2546MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ5497MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ4577MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ3304MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ11363MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ9264MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-130
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW